Viracta Therapeutics, Inc.
(NASDAQ : SNSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.02%735.022.6%$779.43m
MRNAModerna, Inc. 3.36%125.050.0%$634.55m
AMGNAmgen, Inc. 1.03%232.811.4%$630.15m
BIIBBiogen, Inc. 1.10%267.211.8%$593.78m
GILDGilead Sciences, Inc. 3.55%64.531.0%$549.45m
VRTXVertex Pharmaceuticals, Inc. 0.86%299.981.9%$430.51m
ILMNIllumina, Inc. 7.54%201.363.2%$378.78m
SNSSSunesis Pharmaceuticals, Inc. 4.59%4.330.7%$302.68m
SAVACassava Sciences, Inc. 2.22%42.420.0%$201.45m
BNTXBioNTech SE 1.54%138.790.0%$117.05m
NVAXNovavax, Inc. 4.44%19.4375.6%$89.55m
BMRNBioMarin Pharmaceutical, Inc. 0.50%87.144.2%$85.64m
PRTAProthena Corp. Plc 1.53%62.7713.8%$85.29m
NRBONeuroBo Pharmaceuticals, Inc. 1.06%13.400.0%$81.11m
TECHBio-Techne Corp. 2.78%301.214.5%$81.07m

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.